RiverVest Venture Partners — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersSR One Capital Management+7 more
Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.
BiotechHealthtechSan Diego, US
Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)
BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)
Board seatNiall O'Donnell· per SEC Form D · $189.2M raise · filed Oct 2023
Co-investorsNorwest Venture PartnersSofinnova Ventures
InterVene, Inc. is a medical device company that has developed a fully integrated mechanical thrombectomy system to treat venous in-stent restenosis and residual thrombotic venous obstructions and occlusions.
BiotechHealthtechMedical DevicesMountain View, US
Fletcher Wilson(Executive Officer, Director)
BoardThomas Fogarty(Director)Mel Schatz(Director)
Board seatJay W. Schmelter· per SEC Form D
Co-investorsLaunchCapitalTreo Ventures, LlcEmergent Medical Partners, LLP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.